Human research has shown the administration of cortisol into the circulation at rest will result in reduced blood testosterone levels. Many researchers have used these results to imply that physical exercise induced cortisol increases would perhaps result in subsequent reductions in circulating testosterone levels. Our purpose was to examine this concept and determine what, if any, relationship exists between circulating cortisol (C) and testosterone (T) in men (n = 45, 26.3 3.8 yr) at rest and after exercise. Blood samples were collect at rest (10 hour post-prandial; denoted as 'Resting'; n = 45) and again on the same day at 1.0 hr into recovery from intensive exercise (denoted as 'Exercise Recovery'; n = 45). Approximately 48-96 hr after this initial (Trial # 1) blood collection protocol the subjects replicated the exact procedures again and provided a second Resting and Exercise Recovery set of blood samples (Trial # 2). Blood samples from Trial # 1and Trial # 2 were pooled (Resting, n = 90; Exercise Recovery, n = 90). The blood samples were analyzed by radioimmunoassay for C, total T (TT), and free T (fT). Pearson correlation coefficients for the Resting samples ([TT vs. C] r < +0.01; [fT vs. C] r = +0.06) were not significant (p > 0.05). For the Exercise Recovery samples ([TT vs. C] r = -0.53; [fT vs. C] r = +0.21) correlation coefficients were significant (p < 0.05). The findings indicate that exercise does allow the development of a significant negative relationship between C and TT. Interestingly, a significant positive relationship developed between C and fT following exercise; possibly due to an adrenal cortex contribution of fT or disassociation of fT from sex hormone binding globulin. The detected in vivo relationships between C and T, however, were associative and not causal in nature and were small to moderate at best in strength. Key PointsPharmacologically increased levels of cortisol have a significant negative effect on circulating testosteroneAfter certain types of physical exercise a negative statistical associative relationship exist between cortisol and total testosterone.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3880087 | PMC |
Alzheimers Dement
December 2024
Department of Anesthesiology and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, U.S.A., Philadelphia, PA, USA.
Background: The vicious cycle between depression and dementia increases the risk of Alzheimer's Disease (AD) pathogenesis and pathology. This study investigates therapeutic effectiveness versus side effects and the underlying mechanisms of intranasal dantrolene nanoparticles (IDNs) to treat depression behavior and memory loss in 5XFAD mice.
Method: 5XFAD and wild-type B6SJLF1/J mice were treated with IDNs (IDN, 5 mg/kg) in Ryanodex formulation for a duration of 12 weeks.
Background: Abnormal glucose metabolism in AD brains correlates with cognitive deficits. The glucose changes are consistent with brain thiamine (vitamin B1) deficiency. In animals, thiamine deficiency causes multiple AD-like changes including memory loss, neuron loss, brain inflammation, enhanced phosphorylation of tau, exaggerated plaque formation and elevated advanced glycation end products (AGE).
View Article and Find Full Text PDFBackground: Previously, we demonstrated therapeutic benefits following intraperitoneal delivery of the TGR5 agonist HY209 in 5xFAD, a transgenic mouse model of Alzheimer's Disease (AD). Given the desirability of a more acceptable administration route for prolonged AD treatment, we assessed the efficacy of HY209 via oral delivery. This study aims to elucidate the therapeutic potential of NuCerin, an oral formulation of HY209, in the aforementioned AD model, while simultaneously identifying potential blood biomarkers indicative of NuCerin's therapeutic action.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of Southern California, Los Angeles, CA, USA.
Background: Blood pressure (BP) management is an accessible therapeutic target for dementia prevention. BP variability (BPV) is a newer aspect of BP control recently associated with cognitive decline, dementia and Alzheimer's disease (AD), independent of traditionally targeted mean BP levels. Most of this work has relied on largely non-Hispanic White study samples in observational cohorts.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Burke Neurological Institute, Weill Cornell Medicine, White Plains, NY, USA.
Background: Benfotiamine, a prodrug of thiamine, raises blood levels by 50-100 times to achieve pharmacologic effects. It provides a novel therapeutic direction addressing a well-characterized brain tissue thiamine deficiency and related changes in glucose metabolism in AD. BenfoTeam is a seamless phase 2A-2B "proof of concept" (POC), double-blind, placebo-controlled RCT investigating tolerability, safety, and efficacy of benfotiamine, as a first-in-class small molecule treatment for early AD.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!